Since July 2020, multiple drug manufacturers have taken actions that will significantly reduce CHCs’ access to 340B-priced drugs. To date, the Federal Department of Health and Human Services (HHS), which oversees the 340B program, has failed to hold the drug manufacturers accountable.
NOW, manufacturers and others in the pharmaceutical industry, have begun a slander campaign to spread misinformation about the benefits of the 340B program and the use of savings by Covered Entities (CEs). Specifically, there have been false claims that patients have NOT been receiving low-cost drugs and that CEs are misappropriating their savings.